Almirall S.A (E2Z F) stock market data APIs
€11.1901
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Almirall S.A Financial Data Overview
Price chart is built with
Anychart
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Prev. Close
11.1901
Open
11.1901
High
11.1901
Low
11.1901
52 wk Range
7.9466-11.36
Market Cap
2 420 M
P/E Ratio
111
Shares Outstanding
215 M
Revenue
1 054 M
Dividends (Yield)
0.017
Beta
0.34
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Almirall S.A data using free add-ons & libraries
Get Almirall S.A Fundamental Data
Almirall S.A Fundamental data includes:
- Net Revenue: 1 054 M
- EBITDA: 179 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Almirall S.A News
New
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
Almirall’s scientific presence at the 34th EADV congress reflects its broad portfolio of dermatological treatments and patient-centric approach - featuring 44 abstracts, two expert-led symposia on a...
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
Absci Corporation Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations int...
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Absci Corporation Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in ...
Almirall H1 2025 Results
Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by a Strong European Dermatology Business and Increasing Biologics Sales Solid growth ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
